Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
M&A Deal

Azenta Shares Soar 20% in 8 Days Since SynPlexity Acquisition And $71 Million Elegen Deal

Azenta Acquires SynPlexity and Secures $71 Million Elegen Gene Synthesis Deal

+20.28% in 8 days $41.27 when we broke this story → $49.64 at 12:49 PM ET, 11 Nov 2026

Azenta has initiated a multi-stage strategic expansion of its GENEWIZ division by acquiring SynPlexity Inc. and entering an exclusive licensing agreement with Elegen Corp. The total capital deployment, estimated between $32 million and $71 million, is designed to integrate high-throughput gene library technology and cell-free DNA manufacturing into its global service portfolio.

Microscope, investigation, scientific, laboratory. Stock photo illustrating Azenta's M&A deal story.
Azenta, Inc. · Healthcare · Photo: fernandozhiminaicela / Pixabay
Key numbers
Deal value$71M
Share of market cap3.9%
Share of annual revenue12.0%

Key highlights

  • Azenta acquired SynPlexity Inc. to gain pooled gene assembly technology for high-throughput discovery workflows
  • Company entered a five-year exclusive licensing and supply agreement with Elegen Corp. for cell-free DNA manufacturing
  • Total capital deployment is expected to range from $32 million to $71 million based on equipment and licensing options
  • Azenta holds a $25 million option to convert Elegen license rights into a perpetual, irrevocable agreement
  • The investments aim to expand regional production capacity for the company's GENEWIZ gene synthesis business

What Is the Deal?

Azenta, Inc. has executed a dual-track strategic investment to bolster its GENEWIZ multiomics division, combining the acquisition of SynPlexity Inc. with a comprehensive licensing arrangement with Elegen Corp. The consolidated capital deployment for these transactions is projected to range between $32 million and $71 million. While the SynPlexity acquisition brings high-throughput gene library technology in-house, the Elegen agreement provides a five-year exclusive license to proprietary cell-free DNA manufacturing technology. These moves aim to scale regional production capacity and accelerate the delivery speed of synthetic DNA constructs for global pharmaceutical and biotechnology clients.

Deal Structure & Terms

  • Initial deployment covers technology access and equipment purchases for the licensed Elegen platform
  • Azenta holds an option to convert license rights into an irrevocable, perpetual agreement for $25 million
  • Exercise window for the perpetual license conversion is set between 12 and 18 months post-execution
  • Elegen will provide specialized consumables and training services under a Master Services and Supply Agreement
  • The transaction includes specified rights regarding potential future changes of control at Elegen for five years

Strategic Rationale

The integration of SynPlexity’s pooled gene assembly technology allows Azenta to offer thousands of full-length gene variants within a single library, addressing the growing demand for high-capacity biological screening. Simultaneously, Elegen’s cell-free DNA synthesis platform introduces a compact production workflow that reduces the need for traditional cloning, potentially shortening lead times for antibody discovery and protein engineering. By decentralizing manufacturing through these technologies, the company intends to establish localized capacity closer to major customer hubs, mitigating logistical delays and enhancing the scalability of its gene-to-antibody service portfolio.

Financial Context

  • Total investment represents approximately 4% of Azenta’s current $1.81 billion market capitalization
  • Company reported annual revenue of $593.8 million for the 2026 fiscal period
  • Azenta recently completed the $27.5 million acquisition of UK Biocentre Limited in March 2026
  • The divestiture of B Medical Systems for $63 million in late 2025 provided additional capital flexibility
  • Management maintains full-year 2026 revenue guidance between $613 million and $618 million
Azenta, Inc. share price · last month
Line chart of Azenta, Inc.'s share price over the last month, from $34.84 on 19 Oct → $47.22 on 16 Nov; our story on 30 Oct at $41.27.

Up 14.4% since our story on 30 Oct: $41.27 when we broke it → $47.22 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$34.84
20 Oct$35.73
21 Oct$36.76
22 Oct$36.01
23 Oct$36.50
26 Oct$37.17
27 Oct$39.08
28 Oct$40.63
29 Oct$41.27
30 Oct$39.06
2 Nov$35.55
3 Nov$37.14
4 Nov$39.14
5 Nov$37.38
6 Nov$39.16
9 Nov$40.95
10 Nov$40.48
11 Nov$48.90
12 Nov$43.86
13 Nov$45.65
16 Nov$47.22
Earlier announcements by Azenta, Inc.
DateAnnouncementAmount
04 Mar 2026Acquisition of UK Biocentre LimitedSource: SEC filing$27.5 Million
29 Dec 2025Sale of B Medical Systems to Thelema S.à r.l.Source: investors.azenta.com$63.0 Million
12 Nov 2024Plan to divest B Medical SystemsSource: prnewswire.com–

Management commentary

“These strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities we can bring to customers and are key to accelerating our growth.”

Trey Martin, President, Multiomics at Azenta
Azenta, Inc. · financial snapshot
Share price$41.27
Market cap$1.8B
Revenue (annual)$594M
1-month price change+20.39%
SectorHealthcareMedical Instruments & Supplies

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Azenta, Inc. announcing an exclusive licensing agreement with Elegen Corp. and the acquisition of SynPlexity Inc.

Read the filing ↗

Track Azenta, Inc. live

Get the next Azenta, Inc. SEC filing seconds after it lands.

More in M&A & Deals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.